FDA Approval Application for Rivaroxaban by Mankind Pharma
Mankind Pharma has submitted an application for Rivaroxaban under ANDA220874, currently under standard review.
Published: July 10, 2026
Updated: July 10, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Anticoagulant
Company: Mankind Pharma
Asset: Rivaroxaban
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Mankind Pharma
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's review of Mankind Pharma's application for Rivaroxaban marks a significant entry into the anticoagulant market, intensifying competition. This could lead to shifts in pricing strategies and market dynamics that pharma companies must closely observe.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's decision timeline and any subsequent market responses from competitors.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.